Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by PoorOpinionon Jan 15, 2018 11:35pm
105 Views
Post# 27365163

RE:RE:RE:WuXi news

RE:RE:RE:WuXi news
SPCEO1 wrote:
PoorOpinion wrote:
PoorOpinion wrote: https://www.prnewswire.com/news-releases/wuxi-biologics-appoints-dr-chiang-syin-a-former-fda-officer-as-chief-quality-officer-300582386.html

Maybe a little late for us but WuXi look like they are tighten up on their compliance.


 


Actually thinking about it, from his CV, you would think this guy might have insight into how the manufacture assessment might was going. If not directly then maybe through some very close contacts. 

(did I use enough mights and maybes?)


 


Approval is a near certainty but this makes me think the chances of a imminent approval has fallen. I have to think this reflects a reaction to FDA concerns and it might take time to sort it out. Just guessing but that is not the news I wanted to see given the implications for the timing for approvals.


You probably make these appointments to plug gaps but to some extent we know there were gaps, that's why they had to submit extra info in 2017. The appointment of senior personnel probably takes some time (at least a month, idk) so I dont think this is a reaction to something immediate, but I get your point its hard to spin it positive, maybe no need to spin it too negative though.

I mean if the FDA have asked to have certain processes put in place, and WuXi are complying, then it would be natural to include the appointment of certain personnel as part of that process, it could show that meaningful change has happened which would be a positive.

Bullboard Posts